The Main Targets Involved in Neuroprotection for the Treatment of Alzheimer's Disease and Parkinson Disease

Gulcan H. O., ERDOĞAN ORHAN İ.

CURRENT PHARMACEUTICAL DESIGN, cilt.26, sa.4, ss.509-516, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 26 Sayı: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.2174/1381612826666200131103524
  • Dergi Adı: CURRENT PHARMACEUTICAL DESIGN
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Agricultural & Environmental Science Database, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.509-516
  • Anahtar Kelimeler: Neurodegeneration, neuroprotection, amyloidogenic pathway, monoamine oxidase, iron chelator, antioxidant, cholinesterase, NMDA receptor, nitric oxide, AMYLOID PRECURSOR PROTEIN, NITRIC-OXIDE, MONOAMINE-OXIDASE, OXIDATIVE STRESS, MITOCHONDRIAL DYSFUNCTION, COGNITIVE IMPAIRMENT, NEURODEGENERATIVE DISEASES, ANTIOXIDANT PROPERTIES, DIRECTED LIGAND, NMDA RECEPTORS
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

With respect to the total cure failure of current drugs used in the treatment of neurodegenemtive dis- eases, alternative strategies are followed. Particularly, neuroprotection approaches are questioned. Metal chelation, antioxidant towards oxidative stress, modulation of the amyloidogenic pathway, MAO-B inhibition, and NMDA receptor antagonism is more or less typical examples. Some of the representative drug candidates with promising neuroprotective features are assessed in clinical trials. Although initial attempts were found hopeful, none of the candidates have been found successful in each required clinical trials, particularly depending on the failures in terms of cognitive enhancement and slowing the progressive characteristics of neurodegenerative diseases. Today, neuropmtection is evaluated using multi-target ligand-based drug design studies. Within this study, the clinical outcomes of these studies, the rationale behind the design of the molecules are reviewed concomitant to the representative drug candidates of each group.